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ABSTRACT 
Since August 2012, Italian general practitioners are required to prescribe the generic name of 
medicines, except for refill of chronic therapy. We evaluated the extent of switching among 
equivalents in chronic cardiovascular therapies, the influence of the 2012 regulatory 
intervention and of patient-related or drug-related factors. 
Prescription of off-patent antiarrhythmics, oral antidiabetics, and ACE-inhibitors dispensed 
from August 2011 to August 2013 within the Bologna Local Health Authority (870,000 
inhabitants) were collected. The rate of actual switching among equivalents was evaluated 
monthly. The effect of the regulatory intervention was estimated by interrupted time series 
analysis. Adjusted odds ratios (aORs) of switching were calculated for: age, gender, number of 
different equivalents available for each drug, change in dispensing pharmacy between 
subsequent refills. 
The average monthly rates of switches were 9.6%, 16.3%, and 16.3% for antiarrhythmics, 
antidiabetics, and ACE-inhibitors, respectively. Values significantly increased soon after the 
regulatory intervention for ACE-inhibitors (+1.81%, p=0.00), antiarrhythmics (+1.46%, 
p=0.01) and antidiabetics (+1.09%, p=0.01), and no significant decreasing trends were 
observed in the following 12 months. For all drug classes, odd of switching was higher in case 
of change in dispensing pharmacy (up to aOR=4.31, 95CI=4.26-4.35 for ACE-inhibitors) and 
availability of 5 different equivalents (up to aOR=7.82, 95CI=7.39-8.28 for antidiabetics). 
Switching was lower for age 65 for antidiabetics and ACE-inhibitors (aOR=0.92, 95CI=0.90-
0.93; 0.87, 0.86-0.88, respectively). 
The Italian regulatory intervention generated an immediate increase, not sustained in time, in 
switching among equivalents of cardiovascular therapies. Young age, high number of available 
equivalents and changes in dispensing pharmacy between subsequent refills were associated 
with switching. 
INTRODUCTION 
Pharmaceutical expenditure grew by more than 50% in real terms among OECD (Organisation 
for Economic Co-operation and Development) countries during the past decade [1], threatening 
the ability of European healthcare systems to provide comprehensive and equitable healthcare. 
This scenario is likely to worsen across Europe if not properly addressed, driven by well- 
known factors, including ageing populations with increases in non-communicable diseases as 
well as the frequent launch and reimbursement of new premium priced products [2-4]. Many of 
the new medicines are biological products, often priced at between US$100,000 - US$400,000 
(Euro74,000 ± 296,000) per patient per course or year [4-8]. Initiatives and activities instigated 
by health authorities across Europe to optimise the use of available resources include 
developing new models to enhance the appropriate use of new medicines [4] and increasing the 
prescribing of generic medicines, especially in drug class where all the products are seen as 
essentially therapeutically similar at appropriate doses [1,9-18]. This can release considerable 
resources, especially in some European Countries where generic medicines priced as low as 
2% to 5% of pre-patent loss prices are available [19-22]. Strategies to enhance the prescribing 
of generics versus originators include encouraging routine International Non-proprietary Name 
± INN - prescribing (Lithuania and UK), compulsory generic substitution (Sweden), 
substitution targets in community pharmacies (France), preference pricing policies (the 
Netherlands) as well as abolishing co-payments for lower cost generics (Germany and the US) 
[21,23-30]. Encouraging INN prescribing in the UK by starting from medical school has 
resulted in generic consumption as high as 97% to 98% for high volume CV drugs including 
simvastatin, losartan, and lisinopril [25]. 
 
The Italian Government introduced a generic substitution policy in 2001, which obliged 
community pharmacists to inform patients on the cheapest available generic product according 
to the Italian Medicines Agency equivalent lists. In addition, the Agency introduced a reference 
pricing system, with patients having to cover the price difference for a more expensive product 
than the lowest price among the equivalent products available in the regional distribution 
network (internal reference pricing ± IRP [31-34]). IRP system has been now implemented 
among over 20 EU Member States  [31,34,35].   
 
However, despite efforts to  promote the prescribing of equivalents in Italy, the generic market 
is low compared to other European countries. In 2002, generic products accounted for only 
1.2% - 2% of the overall Italian market in value terms [32,33] and 17% of the off-patent 
market. This low volume was due to issues such as co-marketing strategies, with barriers 
generated by different companies marketing the same active ingredient, extended patent 
periods in Italy, and generally higher prices for generics in Italy versus other European 
countries, making it easier for originator companies to lower their prices to compete.  
In August 2012, Italian Government further encouraged the prescribing of generic medicines, 
with a reform requiring Italian GPs to prescribe the generic name (INN) of medicines with  
new medicines. The brand name is only allowed in cases of an explicitly defined need for the 
product or patients with stable chronic disease. Whilst chronic therapies were excluded by the 
rule, concerns about a possible growth in switch rates among equivalents were expressed by 
physicians and others. Controversial issues have been reported on interchangeability, both from 
physicians and patients [36]. It has been argued that substitution with an equivalent product 
should be carefully considered for medicines with a narrow therapeutic index or highly 
variability in bioavailability. However, this only applies to a limited number of medicines as 
seen for instance in the UK with current guidance for INN prescribing [37,38] with, as 
mentioned, very high INN prescribing rates for the majority of molecules where generics are 
available [25].   
Despite continued efforts, in 2013 generics still only accounted for 30% of total reimbursed 
doses and approximately a half of off-patent market [39]. Prices of generics also appeared to 
remain relatively high in Italy, at 40% on the average as compared to pre-patent loss, although 
with differences among therapeutic classes [34].  
 
The aim of this project is to evaluate the extent of switching among equivalents in different 
chronic cardiovascular therapies in Italy, whether the regulatory intervention affected this 
phenomenon and which patient- and drug-related factors can influence the prescribing of 
generics. Findings will be used to provide further guidance to the authorities in Italy and they 
will allow comparisons between Countries with different generic prescription rules and habits. 
Developed methodology could be routinely applied to monitor the impact on future 
interventions on trend cardiovascular generic dispensation and on switching between 
equivalents. 
METHODS 
This is a cross-sectional study based on information coming from administrative databases. 
 
Data source and setting 
Prescription data were extracted from the Drug Reimbursed Database of the Bologna Local 
Health Authority, covering approximately 870,000 of inhabitants. This database collects all 
prescriptions dispensed in the Bologna area and reimbursed to all patients by the National 
Health System.  
 
For this study, we collected and analyzed the prescription of three chronic cardiovascular 
therapies, identified by the Anatomical Therapeutic Chemical Code dispensed from August 
2011 to August 2013. The following classes were considered: ACE-inhibitors (with/without 
diuretics (ATC code: C09A, C09B)), antiarrhythmics (C01B), and oral hypoglycemic agents 
(A10B).  
 
Identification of switches 
For each prescription, the following data were retrieved: patient characteristics (age and 
gender) and drug information (ATC code, dispensing pharmacy, dispensation date, number of 
drug units, and marketing authorisation code). The marketing authorisation code identifies the 
exact dispensed pharmaceutical product (or medicine) and it allows information to be obtained 
on active substance, dosage, pharmaceutical formulation, and package strength, e.g. number of 
tablets into the package.  
By using marketing authorisation codes, we grouped pharmaceutical products on the basis of 
their equivalence in terms of active substance, dosage and  formulation. We referred to the 
equivalent list drawn by the Italian Medicines Agency  
[http://www.agenziafarmaco.gov.it/it/content/liste-di-trasparenza-e-rimborsabilità] as 
validation of our grouping procedure.  
 
From the prescriptive history of each subject, we identified the switches among equivalents: a 
switch was considered when the refill contained an equivalent different from  the previous 
dispensation. Changing in the number of units and changing between originators (named co-
marketing products) was not considered as switching.  
In order to select only patients susceptible of switching between equivalent products, i.e. 
potential switchers, new users of a given therapy and patients receiving medicines without 
generic equivalents were excluded from analyses. The prevalence of switches was calculated 
by considering the actual number of switches on the population of potential switchers.  
 
Time trend analyses 
To evaluate the time trend of switching, for each therapeutic class monthly analyses of the total 
amount of prescriptions and the rate of switches were performed. The effect of the regulatory 
intervention was estimated by the interrupted-time-series methodology. This quasi-
experimental design allows evaluation of dynamic changes in medication use following a 
specific intervention (in our study, it was represented by the regulatory measures taken in 
August 2012) while controlling for secular changes, that may have occurred in the absence of 
the intervention [40]. A 6-month period before and after the intervention was selected 
Differences between the two segmented periods were estimated for (a) level (value of the 
series at the beginning of a given interval), representing a potential early modification in the 
prescription behaviour after the intervention; and (b) trend (slope of a given segment) that 
indicates a potential continuation of the intervention effect. A difference was considered 
statistically significant when the p value of these differences was 0.05.  
 
Analysis of determinants of switches 
To evaluate the determinants of switching among patient-related (age and gender) and drug-
related factors (number of equivalents available on the market for a given drug and change in 
dispensing pharmacy), a logistic regression model was used, by computing crude and adjusted 
odds ratios (ORs) with the relevant 95% confidence intervals (CIs). 
 
  
RESULTS  
 
Overall, a total of 2,230,575  prescriptions were analysed from the Drug Reimbursed Database.  
The total amount of generic dispensations at the end of the observed 2-years period was 
approximately 45% for oral antidiabetics, 38% for ACE inhibitors and 23% for antiarrhythmics 
(Figure 1).  
By looking at the Italian equivalent list, 11 different groups of antidiabetics were identified 
(i.e., different strengths of sulfonylureas, metformin and repaglinide) containing 2 to22 
different equivalents. As for ACE-inhibitors, we dealt with 31 different groups, with 2 to 25 
different equivalents. Among antiarrhythmics, only 4 different equivalent groups were found  
(amiodarone 200mg, propafenone 150mg, propafenone 300mg and flecainide 100mg) with 4 to 
7 different equivalents each one.  
From approximately 27,500 total monthly prescriptions of equivalent antidiabetics (including 
off-patent originators and generics), 86% represented potential switching. As for ACE-
inhibitors, we retrieved approximately 57,900 prescriptions of equivalents per month, with an 
average of 90% potential switching; for antiarrhythmics, out of 3800 monthly prescriptions, 
75% were potential switching (see table in supplementary material).  
Among patients who received a refill of chronic cardiovascular therapies (potential switching), 
mean monthly switch rates were 16.3% for antidiabetics, 16.3% for ACE-inhibitors and 9.6% 
for antiarrhythmics. 
Percentages of switches were higher after the approval of the regulatory intervention. The 
interrupted-time-series analysis showed significant changes in level after the intervention for 
all the considered classes of drugs (level change +1.09; p=0.01 for antidiabetics, +1.46; p0.01 
for antiarrhythmics; +1.81; p=0.00 for ACE-inhibitors). Moreover, we found negligible trend 
decrease in the months after the intervention (trend change -0.01; p=0.92 for antidiabetics; -
0.04; p=0.39 for antiarrhythmics; -0. 06; p=0.21 for ACE-inhibitors), compared with baseline 
(Figure 2). 
 
Table 1 shows the associations between drug-and patient-related factors and the occurrence of 
switching among equivalents. For all drug classes, switching was significantly lower in 
females and in those aged 65 years old. Conversely, this occurrence was higher in cases of 
change in the dispensing pharmacy and increased with increasing number of different 
equivalents. In particular, when more than 5 equivalents for a given medicine were available 
on the market, switching increased by about 30% in case of antiarrhythmics, 100% for ACE-
inhibitors and up to 8-fold for antidiabetics.   
DISCUSSION 
 
Our findings showed a positive trend towards increased use of generics in all considered 
cardiovascular drug classes, with a specific market growth after the Italian regulatory 
intervention on INN name prescription.  However, compared with other European countries the 
use of generics in Italy remains low, especially when considering Germany, Netherlands, 
Sweden and the UK rates, with their different multiple strategies described earlier 
[21,23,25,26,31,41].  
In our cohort, switches among equivalents during chronic cardiovascular therapies ranged 
between 10 and 20% per month and were more frequent for antidiabetic medicines and ACE-
inhibitors as opposed to antiarrhythmics. The clinical significance of these findings represents 
a matter of debate, since there is the theoretical risk of important variations in drug 
bioavailability if switches occur among equivalents with varying AUCs of the drug. As known, 
the AUCs of an equivalent drug may vary by 20% as compared to the originator: while a 
simple change from originator to an equivalent will have limited impact on clinical response, 
sequential switching among equivalents along with time could induce large variations in drug 
effect that, in case of drugs with low therapeutic index (e.g. antiarrhythmic agents), could have 
higher influence on benefit-risk profile.  
As a matter of fact, different authors showed no difference in outcomes between originators 
drugs used to treat patients with cardiovascular diseases in their meta-analysis versus generics 
[42,43].Concerning a condition usually considered as a reference for the high risk of impaired 
outcomes in case of pharmacokinetic changes, no differences were also seen between 
originators and generic medicines used to treat patients with epilepsy [37,38,44].  The Italian 
League against Epilepsy working group on generic products of antiepileptic drugs (AEDs) 
concluded that generic AEDs meeting current regulatory criteria for bioequivalence represent a 
valuable choice in the management of epilepsy particularly in patients initiating monotherapy 
or adjunctive treatment and in those with persistent seizures. However, concerns remain when 
patients have achieved seizure remission as well as in case of regular switches between 
different formulations of the same molecule [45] and this led to recent advice from the UK 
government [46].  
In patients with arrhythmia, prescribers also prefer to avoid substitution between generics from 
different manufacturers. The risk associated with frequent switches among generics could be 
higher in the frail elderly population, since kinetic variations can easily impair the risk-benefit 
profile and precipitate drug-drug interactions. Care is also needed since switches in brand 
during refills can cause patient confusion leading potentially to duplication of dosage [47]. 
Routine INN prescribing help avoids this confusion [48].     
Education initiatives for pharmacists and patients are needed to avoid unnecessary switches 
among equivalent drugs throughout critical chronic therapy, e.g. empowerment of the patient 
on the importance to remember the medicinal product used, especially in case of 
antiarrhythmics. On the other hand, substitution could be acceptable if clear information on the 
equivalence is provided by the pharmacist.  
 
Notably, our data showed a lower frequency of switches in the elderly, with consequent 
mitigation of clinical risks. The reason(s) for this might be a specific attention by physicians to 
drug therapies in this population. Another contributing factor could be the habits of the patient 
to place their prescription at the same pharmacy, where the support of pharmacist in 
maintaining the same brand might reduce switching. Further research is need though before 
any definitive statements can be made. 
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market  significantly influenced the switching phenomenon. Although this result can be 
considered as predictable (at least on the basis of probability), it should represent matter of 
concern for regulators and generic companies. A limited number of equivalents for each off-
patent medicine, e.g., 5 equivalents, could both facilitate the use of generics and limit the 
clinical risk derived from switching. However, it is difficult to make a definitive statement 
regarding this given for instance the high level of INN prescribing in the UK, apart from a 
limited number of cases, without apparent problems for patients [38]. Competition and 
transparency in pricing has also resulted in low prices for generics in the UK [25,49]. 
 
Our study did not include an outcome analysis, and the evaluation of the clinical consequences 
of switching was beyond the scope of this work. This is because we focused on developing 
methodology easily applicable by local health authorities in routine activity of monitoring drug 
utilization patterns, when only prescription data are available. Future studies, based on record 
linkage analyses including exposure and hospital admission data, will be undertaken to 
evaluate the possible impact of switching among equivalents on clinical outcomes, although we 
do not expect to see major differences in outcomes, as showed by already mentioned articles 
[42-44]. 
 
Price difference among equivalents could represent an additional factor influencing the rate of 
generic prescription and switching phenomenon. In the literature, different points of view are 
reported: patients could prefer to use generics because of the low cost, and also adherence to 
the therapy could increase with low-price generics [27,28]. On the other hand, patients 
(probably influenced by prescribers) could prefer to pay for drugs, since they ascribe high 
quality to the high cost of originator or other more expensive equivalents. However, there is 
variable  correlation between generic prices and their use among European Countries, with 
countries with high market share of generics typically having lower prices [31,50]. If doubts on 
the quality of generic medicines is a possible reason for their low use, strategies must be 
implemented by health authorities to address this and appear to have worked well in France 
and Portugal [30], providing guidance to countries where this is a concern. 
In conclusion, a number of measures can be applied in Italy to further increase equivalent 
prescribing.  Since significant monthly switching between equivalents can generate concerns, 
not supported by clinical evidence, on the risk of kinetic variations and errors in drug intake, 
information campaigns should be promoted to encourage generic dispensation and explain 
behaviors to be observed by patients. The large number of equivalent products of the same 
originator is a matter of concern for prescribers and pharmacists about possible mistakes by 
patients: it is not easy to address this in the current regulatory framework of generic medicinal 
products. 
Figure 1. Percentage of dispensed generics in different cardiovascular drug classes  
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Figure 2 - Interrupted-time-series analysis on the monthly trend in switching across the 
Italian regulatory intervention on generic prescribing 
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Table 1. Logistic regression analysis on the factors influencing the frequency of switching  
  Oral antidiabetic agents  
OR and 95% CI 
ACE inhibitors 
OR and 95% CI 
Antiarrhythmics 
OR and 95% CI 
  Crude Adjusted Crude Adjusted  Crude Adjusted 
Gender             
Male 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Female 0.96 (0.95-0.98) 0.97 (0.95-0.98) 0.93 (0.92-0.94) 0.95 (0.94-0.96) 0.93 (0.89-0.98) 0.93 (0.89-0.98) 
Age             
<65 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
65 0.86 (0.85-0.88) 0.92 (0.90-0.93) 0.81 (0.80-0.80) 0.87 (0.86-0.88) 0.99 (0.93-1.05) 0.96 (0.90-1.03) 
Change in 
dispensing 
pharmacy 
            
No 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Yes (each change 
from territory to osp 
and vice versa) 
3.45 (3.43-3.53) 3.49 (3.44-3.54) 4.32 (4.28-4.37) 4.31 (4.26-4.35) 3.62 (3.44-3.82) 3.64 (3.46-3.84) 
N. of marketed 
equivalents 
            
0-5 (0) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
6-10 (1) 7.69 (7.27-8.14) 7.82 (7.39-8.28) 1.84 (1.78-1.89) 1.98 (1.92-2.04) 1.27 (1.21-1.34) 1.31 (1.24-1.39) 
>10 (2) 7.79 (7.38-8.24) 7.92 (7.50-8.38) 1.91 (1.86-1.96) 1.98 (1.93-2.04) - - 
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